Author pages are created from data sourced from our academic publisher partnerships and public sources.
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
- R. Heine, L. V. Van Gaal, D. Johns, M. Mihm, M. Widel, R. Brodows
- Annals of Internal Medicine
- 18 October 2005
Context Are both exenatide and insulin glargine reasonable additions for patients with type 2 diabetes that is suboptimally controlled despite metformin and sulfonylurea therapy? Contribution This… Expand
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
- W. P. James, I. Caterson, +8 authors C. Renz
- The New England journal of medicine
- 1 September 2010
BACKGROUND The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. … Expand
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic… Expand
Human leptin: from an adipocyte hormone to an endocrine mediator.
- M. Wauters, R. Considine, L. V. Van Gaal
- Biology, Medicine
- European journal of endocrinology
- 1 September 2000
Leptin is a mainly adipocyte-secreted protein that was discovered 5 years ago. Most of the research following this discovery focused on the role of leptin in body weight regulation, aiming to… Expand
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- A. Astrup, R. Carraro, +9 authors L. V. Van Gaal
- International Journal of Obesity
- 16 August 2011
Objective:Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight… Expand
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients
- L. V. Van Gaal, X. Pi-Sunyer, Jean‐Pierre Després, C. Mccarthy, A. Scheen
- Diabetes Care
- 1 February 2008
OBJECTIVE—To better define the efficacy and safety of rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, in a large population of overweight and obese patients using pooled… Expand
Autoimmune gastritis in type 1 diabetes: a clinically oriented review.
CONTEXT Autoimmune gastritis and pernicious anemia are common autoimmune disorders, being present in up to 2% of the general population. In patients with type 1 diabetes or autoimmune thyroid… Expand
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
- M. Diamant, L. V. Van Gaal, +5 authors M. Trautmann
- The lancet. Diabetes & endocrinology
- 1 June 2014
BACKGROUND When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3,… Expand
Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution
- S. Verhulst, N. Schrauwen, +5 authors K. Desager
- Archives of Disease in Childhood
- 13 October 2006
Aims: To determine the prevalence of sleep-disordered breathing (SDB) in a clinical sample of overweight and obese children and adolescents, and to examine the contribution of fat distribution.… Expand
Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
BACKGROUND & AIMS The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased with the obesity pandemic. We analyzed the transcriptional profiles of subcutaneous adipose tissue (SAT) and… Expand